HomeTagsJohnson & Johnson

Tag: Johnson & Johnson

biotech

Johnson & Johnson prostate cancer drug receives CHMP positive opinion

Jim Cornall - February 5, 2026

biotech

First precision therapy prostate cancer drug approved

Jim Cornall - December 17, 2025

biotech

CRS programme to feature Poolbeg Pharma trial

Jim Cornall - December 11, 2025

biotech

“Turning point in how we treat EGFR-mutated lung cancer”

Jim Cornall - September 10, 2025

biotech

Johnson & Johnson aiming to revolutionise plaque psoriasis treatment

Jim Cornall - July 24, 2025

biotech

Johnson & Johnson receives Priority Review for high-risk non-muscle invasive bladder cancer treatment

Jim Cornall - July 22, 2025

- Advertisement -

spot_img

Latest Articles

biotech

Antibody targeting TSLP achieves positive results in asthma study

biotech

Clinical trial shows knee osteoarthritis pain improvement

biotech

Preclinical paper on CD73 small molecule inhibitor

biotech

Positive results from relapsed/refractory B-cell lymphoma trial

biotech

EpilepsyGTx and Viralgen collaborating on AAV gene therapy epilepsy programme